FDA Final Guidance on Prescription Drug Apps and Software
- Date
- October 21, 2026
- Category
US Regulations
- Description
On 20 October 2026, the FDA released Federal Register :: Regulatory Considerations for Prescription Drug Use-Related Software; Guidance for Industry; Availability establishing a clear framework for how drug companies can develop, distribute, and label apps used alongside their prescription medicines. The guidance ends longstanding uncertainty by providing recommendations about when app content is subject to FDA submission requirements, when an app should be mentioned on a drug’s official label, and what companies should submit to the agency.
“Mobile apps are playing a growing role in how patients manage their medications and health conditions,” said Captain Chris Wheeler, Pharm.D., Director of the Division of Medical Policy Programs within CDER. “This guidance helps ensure that the information these tools provide is accurate, evidence-based, and clearly communicated to both patients and their providers.”
The guidance addresses three key questions for industry: when app content is treated as FDA-required labelling versus promotional labelling, when an app should be referenced in a drug’s official prescribing information, and what companies should submit to FDA when they distribute app content to users.
The guidance identifies two categories of companion software:
- Apps connected to a medical device (such as an app paired with an asthma inhaler) generally should be described on the drug’s official prescribing label, given the central role the software plays in how the medicine is used.
- Standalone apps (such as symptom trackers, dose reminders, or health coaching tools) should appear on the prescribing label if the company can show the app is essential for safe and effective use or can demonstrate a meaningful clinical benefit. In most cases, content a companion app displays to users will be treated as promotional material, consistent with how the FDA handles other drug advertising.